Stay updated on ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial
Sign up to get notified when there's something new on the ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial page.

Latest updates to the ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial page
- Check3 days agoChange DetectedNotice added about government funding lapse affecting data currency; page revision updated to v3.4.1.SummaryDifference0.5%

- Check10 days agoChange DetectedAdded a Show glossary option and minor metadata label updates (Last Update Submitted that Met QC Criteria; No FEAR Act Data; Revision: v3.4.0), and removed older terms with different capitalization/wording (Last Update Submitted that met QC Criteria; No FEAR Act data; Revision: v3.3.4).SummaryDifference0.2%

- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedThe page revision indicator changed from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check46 days agoChange DetectedFooter/site metadata updated: Revision v3.3.3 added; HHS Vulnerability Disclosure link removed and Revision v3.3.2 removed, with no impact on study content or user actions on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check68 days agoChange DetectedThe page shows an updated revision from v3.3.1 to v3.3.2, indicating a minor update to the study record. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check75 days agoChange DetectedAdded revision label v3.3.1 and removed revision label v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ECT-Pembrolizumab for Unresectable Melanoma Clinical Trial page.